
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc demonstrates a strong outlook due to its innovative PREDATOR platform, which enables the development of therapeutics that precisely activate immunity within the tumor microenvironment, addressing critical gaps in existing cancer treatments. The company's strategic advancements and proprietary technology foster confidence in its potential to deliver groundbreaking therapies, thereby appealing to investors interested in the biopharmaceutical sector. Additionally, Werewolf's focus on conditionally activated INDUKINE molecules highlights its commitment to enhancing therapeutic efficacy while minimizing off-target effects, indicating a strong foundation for future revenue growth and market differentiation.
Bears say
Werewolf Therapeutics is facing a challenging financial outlook as reflected in the weak performance metrics. Specifically, the company experienced a revenue decline of 30 basis points year-over-year, coupled with a significant 3.8% increase in expenses, leading to a net operating income (NOI) decline of 2.6%. Additionally, the average effective rental rate decreased by 50 basis points year-over-year, driven by a substantial drop in new lease rates, which raises concerns about the company’s ability to generate sufficient revenue moving forward.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares